RAP-219 — Topline data
October 2026
The Phase 2 trial continues to progress, with topline results expected in October 2026.Source filing
RAPP biotech catalysts & pipeline
RAPPORT THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
RAP-219 — Initial data
Q4 2026
The majority of patients from the RAP-219 Phase 2 trial in FOS have now enrolled in the open-label long term safety trial, with initial data expected in the fourth quarter of 2026.Source filing
RAP-219 — Initial data
2027
IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027.Source filing